MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3408-3419

  Morse, Michael A ^a   Secord, Angeles A ^a   Blackwell, Kimberly ^a   Hobeika, Amy C ^a   Sinnathamby, Gomathinayagam ^b   Osada, Takuya ^a   Hafner, Julie ^b   Philip, Mohan ^b   Clay, Timothy M ^a   Lyerly, H Kim ^a   Philip, Ramila ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Immunotope Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; CARBON DIOXIDE; CHLORIDE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HLA A2 ANTIGEN; IMT 1012; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONTANIDE ISA 51; NITROGEN; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; PLATINUM COMPLEX; TAXANE DERIVATIVE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UREA;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANOREXIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANXIETY; ARTHRALGIA; ARTICLE; BLOATING; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER PATIENT; CARBON DIOXIDE BLOOD LEVEL; CELLULAR IMMUNITY; CHEILITIS; CHILL; CHRONIC DISEASE; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CYSTITIS; DEPRESSION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HLA MATCHING; HUMAN; HUMAN CELL; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; JAUNDICE; LEUKOCYTOSIS; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHADENOPATHY; MENTAL DISEASE; MOUTH PAIN; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; ODOR; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEOMICS; PRURITUS; RESTLESS LEGS SYNDROME; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; TUMOR IMMUNITY; UREA NITROGEN BLOOD LEVEL; URINE INCONTINENCE; WEIGHT GAIN;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEOMICS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79956018406     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2614     Document Type: Article

References (46)

1. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 2002;25:189-201. (Pubitemid 34533308)
2. Kammerer U, Thanner F, Kapp M, Dietl J, Sutterlin M. Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res 2003;23:1051-5. (Pubitemid 36750918)
3. Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, et al. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol Immunol 1998;35:1121-33. (Pubitemid 29057151)
4. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ, Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994;152:2393-400. (Pubitemid 24097931)
5. Nijman HW, van Diest PJ, Poort-Keesom RJ, von Mensdorff-Pouilly S, Verstraeten RA, Kummer A, et al. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2001;94:114-20. (Pubitemid 32008009)
6. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
7. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor Wharton J, Freedman R.S.Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on nonovarian tumour clones. Scand J Immunol 1993;37:413-24. (Pubitemid 23105273)
8. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-90. (Pubitemid 24225955)
9. Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, et al. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 2003;52:771-9. (Pubitemid 37491705)
10. Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U, Krebs D. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 1997;16:33-40. (Pubitemid 27148687)
11. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, et al. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003;9:3222-34. (Pubitemid 37082716)
12. Emens LA, Jaffee EM. Toward a breast cancer vaccine: work in progress. Oncology (Huntington) 2003;17:1200-11.
13. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004;16:87-92. (Pubitemid 38241547)
14. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32. (Pubitemid 34575634)
15. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002;30:95-102.
16. Parker LL, Do MT, Westwood JA. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11:2377-87.
17. Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, et al. Long term disease-free survival and T cell and antibody responses in women with high-risk HER2+ breast cancer following vaccination against HER2+. J Transl Med 2007;5:42-51.
18. Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003;189:28-36. (Pubitemid 36886520)
19. Reinartz S, Kóhler S, Schlebusch H, Krista K, Giffels P, Renke K, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10:1580-7. (Pubitemid 38435546)
20. Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 2002;20:463-93. (Pubitemid 34293432)
21. Admon A, Barnea E, Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2003;2:388-98.
22. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
23. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-23.
24. Boon T.Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993;54:177-80.
25. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
27. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003;15:751-63.
28. Armstrong DK. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 2002;7:20-28.
29. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008;14:2740-8.
30. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-14.
31. Chianese-Bullock KA, Irvin WP, Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008;31:420-30.
32. Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.J Immunol 2005;174:3080-6.
33. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-51.
34. Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol 2005;175:12.
35. Atzpodien J, Fluck M, Reitz M. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Cancer Biother Radiopharm 2004;19:758-63.
36. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005;54:208-18.
37. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004;9:207-15.
38. Schiffman K, Disis ML. HER2/neu peptide-based vaccines, with GMCSF as an adjuvant, in patients with advanced-stage HER2/neuexpressing cancers. Clin Lung Cancer 2000;2:74-7.
39. Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
40. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003;104:188-94.
41. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003;97:186-200.
42. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8:3407-18.
43. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
44. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010;9:519-25.
45. Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009;15:7036-44.
46. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-32.